ImmunoGen, Inc. (IMGN) Appoints David Johnston As Chief Financial Officer
12/30/2013 6:20:21 AM
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its industry leading antibody-drug conjugate (ADC) technology, today announced the appointment of David Johnston as Executive Vice President and Chief Financial Officer, effective today. Mr. Johnston brings to ImmunoGen more than 30 years of experience in corporate finance, including 15 years in senior financial functions at biotechnology companies, as well as extensive experience in corporate planning. He reports to Daniel Junius, President and Chief Executive Officer of ImmunoGen.
Help employers find you! Check out all the jobs and post your resume.
comments powered by